NDA 018859 · Bausch
Virazole
Ribavirin · Inhalation · Nucleoside Analog Antiviral
NovelPriority reviewDiscontinuedLast checked: Nov 20, 2026Latest source record: Jan 6, 2016 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1985
Dec 31, 1985
Approved uses
2
Original approval plus efficacy supplements
Registered trials
921
305 Phase 3, 6 recruiting
FAERS reports
63,955
37,984 serious, 3,419 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNINGS USE OF AEROSOLIZED RIBAVIRIN FOR INHALATION SOLUTION, USP IN PATIENTS REQUIRING MECHANICAL VENTILATOR ASSISTANCE SHOULD BE UNDERTAKEN ONLY BY PHYSICIANS AND SUPPORT STAFF FAMILIAR WITH THE SPECIFIC VENTILATOR BEING USED AND THIS MODE OF ADMINISTRATION OF THE DRUG. STRICT ATTENTION MUST BE PAID TO PROCEDURES THAT HAVE BEEN SHOWN TO MINIMIZE THE ACCUMULATION OF DRUG PRECIPITATE, WHICH CAN RESULT IN MECHANICAL VENTILATOR DYSFUNCTION AND ASSOCIATED INCREASED PULMONARY PRESSURES (SEE WARNINGS ). SUDDEN DETERIORATION OF RESPIRATORY FUNCTION HAS BEEN ASSOCIATED WITH INITIATION OF AEROSOLIZED RIBAVIRIN FOR INHALATION SOLUTION, USP USE IN INFANTS. RESPIRATORY FUNCTION SHOULD BE CAREFULLY MONITORED DURING TREATMENT. IF INITIATION OF AEROSOLIZED RIBAVIRIN FOR INHALATION SOLUTION, USP TREATMENT APPEARS TO PRODUCE SUDDEN DETERIORATION OF RESPIRATORY FUNCTION, TREATMENT SHOULD BE STOPPED AND...
What it is approved for
From the label in effect May 1, 2019.
INDICATIONS AND USAGE Ribavirin for Inhalation Solution, USP is indicated for the treatment of hospitalized infants and young children with severe lower respiratory tract infections due to RSV. Treatment early in the course of severe lower respiratory tract infection may be necessary to achieve efficacy. Only severe RSV lower respiratory tract infection should be treated with Ribavirin for Inhalation Solution, USP. The vast majority of infants and children with RSV infection have disease that is mild, self-limited, and does not require hospitalization or antiviral treatment. Many children with mild lower respiratory tract involvement will require shorter hospitalization than would be required for a full course of Ribavirin for Inhalation Solution, USP aerosol (3 to 7 days) and should not be treated with the drug. Thus the decision to treat with Ribavirin for Inhalation Solution, USP should be based on the severity of the RSV infection. The presence of an underlying condition such as prematurity, immunosuppression or cardiopulmonary disease may increase the severity of clinical manifestations and complications of RSV infection. Use of aerosolized Ribavirin for Inhalation Solution, USP in patients requiring mechanical ventilator assistance should be undertaken only by physicians and support staff familiar with this mode of administration and the specific ventilator being used (see WARNINGS and DOSAGE AND ADMINISTRATION ). Diagnosis RSV infection should be documented by a rapid diagnostic method such as demonstration of viral antigen in respiratory tract secretions by immunofluorescence 3,4 or ELISA 5 before or during the first 24 hours of treatment. Treatment may be initiated while awaiting rapid diagnostic test results. However, treatment should not be continued without...
Mechanism: Mechanism of Action In cell cultures the inhibitory activity of ribavirin for respiratory syncytial virus (RSV) is selective. The mechanism of action is unknown. Reversal of the in vitro antiviral activity by guanosine or xanthosine suggests ribavirin may act as an analogue of these cellular metabolites. Microbiology Ribavirin has demonstrated antiviral activity against RSV in vitro 1 and in experimentally infected cotton rats. 2 Several clinical isolates of RSV were evaluated for ribavirin susceptibility by plaque reduction in tissue culture. Plaques were reduced 85-98% by 16 mcg/mL;...
Therapeutic areas: Infectious disease and vaccines
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 5, 1993 Supplement 3 · Efficacy
- Dec 31, 1985 Original approval · Type 1 - New Molecular Entity · priority review Review
1 products under this application
- VIRAZOLE · RIBAVIRIN 6GM/VIAL · FOR SOLUTION, INHALATION · Discontinued · TE AN
Clinical trials
Interventional ClinicalTrials.gov studies with "Ribavirin" as an intervention, any sponsor and status, largest first.
- Management of Patients With Hepatitis C in a Public Health Care Setting: The Punjab ModelStatus unknown
Post Graduate Institute of Medical Education and Research, ChandigarhAcademic, hospital or other
NCT03488485 · 50,000 participants (planned) · Start Jun 18, 2016 · Primary completion Dec 2020
Drug: Direct Acting Antivirals · For: Chronic Hepatitis c
Sites: Chandigarh, India
- Safety and Efficacy of Sofosbuvir-Based Regimens in the Treatment of Egyptian Patients With Hepatitis C InfectionPivotal-lookingCompleted
Tanta UniversityAcademic, hospital or other
NCT02992457 · 10,000 participants · Start Jan 2015 · Primary completion Dec 2018
Drug: Sofosbuvir; Ribavirin and 6 more · For: Hepatitis C
Sites: Tanta, Egypt · 2 sites in all
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT00922779 · 6,661 participants · Start Jun 2002 · Primary completion Jun 2012
Drug: peginterferon alfa-2a [Pegasys]; ribavirin · For: Hepatitis C, Chronic
Sites: Arkhangelsk, Russia; Barnaul, Russia; Blagoveshchensk, Russia · 93 sites in all
- Hansenula-derived Pegylated Interferon in Treatment of Patients With Chronic Hepatitis CStatus unknown
MinaPharm PharmaceuticalsIndustry
NCT01649245 · 5,000 participants (planned) · Start Aug 2012 · Primary completion Aug 2014
Drug: Reiferon retard · For: Chronic Hepatitis C
Sites: Shebin El-Kom, Egypt
- Comparison of PEG-Intron and Two Different Doses of Ribavirin for the Treatment of Chronic Hepatitis C In Treatment Naïve SubjectsPivotal-lookingCompleted
Weill Medical College of Cornell UniversityAcademic, hospital or other
NCT00299936 · 5,000 participants
Drug: Ribavirin, PEG-Intron · For: Chronic Hepatitis C
- Peginterferon Dose Evaluations for Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03471)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT00081770 · 4,469 participants · Start Mar 2004 · Primary completion Nov 2007
Drug: PegIntron (peginterferon alfa-2b; SCH 54031); PegIntron (peginterferon alfa-2b; SCH 54031) and 3 more · For: Hepatitis C, Chronic
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT00940420 · 2,695 participants · Start Oct 2002 · Primary completion Nov 2009
Drug: Copegus (ribavirin); Copegus (ribavirin) and 2 more · For: Hepatitis C, Chronic
Sites: Afula, Israel; Ashkelon, Israel; Bat Yam, Israel · 20 sites in all
- PEG-Intron Plus Rebetol Treatment of Chronic Hepatitis C Subjects Who Failed Response to Alpha-Interferon Plus Ribavirin (Study P02370)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT00039871 · 2,333 participants · Start May 2002 · Primary completion Sep 2007
Drug: PegIntron (peginterferon alfa-2b; SCH 54031); REBETOL (ribavirin; SCH 18908) · For: Hepatitis; Hepatitis C, Chronic; Fibrosis and 1 more
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- fatigue9,564
- anaemia8,370
- nausea7,440
- rash5,358
- headache4,795
- pruritus4,647
- vomiting3,810
- diarrhoea3,751
- asthenia3,618
- pyrexia3,583
- white blood cell count decreased3,443
- insomnia3,439
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 392 |
| 2005 | 622 |
| 2006 | 686 |
| 2007 | 920 |
| 2008 | 1,230 |
| 2009 | 1,196 |
| 2010 | 964 |
| 2011 | 1,403 |
| 2012 | 13,701 |
| 2013 | 9,239 |
| 2014 | 4,843 |
| 2015 | 13,685 |
| 2016 | 5,553 |
| 2017 | 2,869 |
| 2018 | 2,639 |
| 2019 | 1,485 |
| 2020 | 815 |
| 2021 | 505 |
| 2022 | 417 |
| 2023 | 236 |
| 2024 | 268 |
| 2025 | 178 |
| 2026 | 104 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Ribavirin for Treatment of Subjects with Respiratory Syncytial Virus-Related Infection: A Systematic Review and Meta-Analysis.
Tejada S, Martinez-Reviejo R, Karakoc HN, et al. · Adv Ther 2022 · Meta-Analysis, Systematic Review
- Ribavirin for treating Crimean Congo haemorrhagic fever.
Johnson S, Henschke N, Maayan N, et al. · Cochrane Database Syst Rev 2018 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Ribavirin (Virazole).
· Med Lett Drugs Ther 1986 · Clinical Trial
- Therapy of allergic rhinitis using ribavirin spray to clear nasal commensal viruses.
Zhou Y, Wang T, Fan Y, et al. · Signal Transduct Target Ther 2026 · Randomized Controlled Trial
- Ribavirin Does Not Enhance Hepatitis B Virus Nucleotide Antiviral Activity: A Pilot Study.
Keeshan A, Coffin C, Vachon A, et al. · Clin Invest Med 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Novel combined single dose anti-hepatitis C therapy: a pilot study.
Shiha G, Soliman R, Elbasiony M, et al. · Sci Rep 2021 · Clinical Trial, Phase III, Randomized Controlled Trial
Sponsor: Bausch
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.